DataPile investor atlas

Angel investors & venture capitalists in United States

Last updated 04-10-2025. Data refreshed weekly.

16 Matches for your filters
3,050 Total investors in region
3,050 Profiles tracked nationwide
San Francisco (84) Largest investor hub
Andreessen Horowitz, Insight Partners Notable firms

Refine investor results

Toggle multiple filters to narrow the directory instantly.

Location

States & regions

Cities

Industry focus

We found 16 investors focused on research.

Market intelligence

  • Most active investment themes in United States: venture capital & private equity, investment banking, investment management.
  • 84 profiles are headquartered in San Francisco, making it the busiest hub in United States.
  • Featured firms include Andreessen Horowitz, Insight Partners, General Catalyst, Bain Capital Ventures.

Explore states in United States

Showing 1 – 16 of 16 investors

Adam Meyers profile photo Biogen logo
Adam Meyers
Head of Immunology and New Disease Areas Franchise; Biogen Foundation Board of Directors
Biogen
Focus areas
research biotechnology life sciences biotechnology: biological products (no diagnostic substances) health care biotechnology research biotech for lupus biotech biotech leadership biotech company clinical research biotech manufacturing neurodegenerative diseases biotech r&d biotech for neurodegenerative diseases mental health biotech patient care biotech clinical research drug development tau pathology biotech innovation biotech biotech mergers biotech therapies neuroscience innovation biotech for sma research and development in the physical engineering and life sciences biotech biotech r&d rare diseases biotech health impact biotech biotech manufacturing biotech acquisitions biotech biotech collaborations biotech biotech mergers b2b biotech collaborations manufacturing biotech pipeline biotech for rare genetic disorders biotech biotech acquisitions biotech market biotech biotech market neurodegeneration patient care biotech biotech hub clinical trial innovation biotech products biotech innovation strategy biotech regulatory approval clinical trials biotech for alzheimer's biotech for kidney disease rare disease treatments neuroscience biotech pipeline management antisense oligonucleotides biotech innovation ecosystem healthcare pharmaceuticals biotech treatments biotech biotech innovation biogen biotech research biotech sustainability biotech corporate responsibility blood-based biomarkers biotech drug development biotech research and development biotech for ms biotech leadership neurotherapeutics biotech for postpartum depression biopharmaceuticals biotech industry services rare genetic disorders biotech biotech pipeline alzheimer's disease amyotrophic lateral sclerosis friedreich ataxia lupus multiple sclerosis postpartum depression spinal muscular atrophy biologics medicines research and development biosimilars health equity patient support programs r&d expertise therapeutic solutions innovative therapies early access programs health disparities cognitive screening autoimmune diseases immunological pathways diversity equity inclusion community health programs safety information enhanced quality of life transformative medicines functional outcomes neuroimmunology medical professionals drug efficacy patient recruitment investigational therapies scientific collaborations creative healthcare solutions personalized medicine genetic variants preventative care support networks health wellness & fitness hospital & health care mechanical or industrial engineering medical research & development
Location
Cambridge, Massachusetts, United States
Signals
Andy Feng profile photo Cambrian Bio logo
Andy Feng
Venture Capital
Cambrian Bio
Focus areas
research biotech aging science aging biology healthcare longevity longevity science disease prevention innovation geroscience healthspan pharma
Location
New York, New York, United States
Signals
Bob Otto profile photo Oak Ridge National Laboratory logo
Bob Otto
Advisory Board Member, Global Security Directorate
Oak Ridge National Laboratory
Focus areas
research computing biosciences reactors science nuclear energy neutron science chemistry climate mathematics fusion astrophysics clean energy high performance computing 3d printing additive manufacturing advanced manufacturing software nanoscience mass spectrometry climatechange materials nuclear science artificial intelligence research services research and development advanced materials energy solutions national security high-performance computing bioenergy technologies environmental science systems biology scientific innovation technology transfer materials science supercomputing interdisciplinary research economic development collaborative partnerships infrastructure protection robotics quantum computing isotope production sustainability workforce diversity scientific breakthroughs energy security public safety advanced testing facilities environmental sustainability talent development community engagement scientific outreach innovation initiatives autonomous laboratories cybersecurity solutions research energy biological sciences computational sciences fusion energy fission energy isotope research renewable energy energy storage collaboration scientific discovery engineering r&d bioeconomy data analysis emergency management sustainable development climate change innovation transportation technologies grid modernization building technologies program development strategic partnerships educational programs community resilience workforce development economic growth risk management environmental protection small business programs energy efficiency biodiversity digital technology automated systems encryption technology b2b government services environmental services renewables & environment information technology & services research & development material science mechanical or industrial engineering clean energy & technology oil & energy data analytics
Location
Gig Harbor, Washington, United States
Signals
CH
Christopher Hong
Investor
OpenAI
Focus areas
research artificial intelligence & machine learning research services ai in startups ai collaboration ai in healthcare ai for business ai model api ai deployment ai model fine-tuning market research ai for data analysis ai model safety services ai for startups software development ai for automation ai for real-world interaction ai for personalized education ai models api ai for enterprises financial technology ai in finance content generation ai for research ai for medical research ai collaboration tools ai bias mitigation research and development in the physical engineering and life sciences ai scalability video generation models ai tools multimodal ai healthcare technology ai technology ai research community ai for healthcare ai infrastructure information technology and services ai models synthetic voices machine learning government ai responsible ai ai api platform ai applications ai for content creators ai for customer support ai model optimization ai solutions ai safety ai in industry ai model training gpt-4 reinforcement learning ai for education ai for content generation ai research ai innovation ai automation tools ai development ai safety protocols ai safety measures ai content creation ai for legal professionals ai model evaluation ai for decision making ai ethics ai ethics guidelines agi safety ai for social good ai model security b2b ai ai for finance chatgpt ai multimodal d2c cloud computing ai safety research ai creative applications ai for developers ai for scientific discovery ai in creative arts e-commerce ai model innovation b2c ai for language understanding ai model collaboration ai developer tools ai model customization gpt models ai for speech recognition natural language processing ai creative tools deep learning consulting ai for productivity artificial intelligence openai api ai for visual content ai model robustness ai productivity tools ai in education ai model deployment ai in enterprise ai multimodal inputs retail ai apis ai for enterprise solutions ai model interpretability ai model integration multimodal models ai model multimodal ai for environmental monitoring research and development education technology ai responsible development content creation ai model scalability openai sora text-to-video data analysis image generation api integration enterprise ai customizable ai models business productivity collaborative tools workforce empowerment financial analysis education ai academic research advanced ai tools task automation coding assistance multimedia understanding business insights team collaboration safety in ai ethical ai deployment customer service ai training datasets document summarization social implications of ai creative brainstorming personalized learning ai voice interaction image understanding secure ai solutions siri integration real-time reasoning custom gpts memory management in ai ai productivity user-friendly ai ai-driven insights enterprise-grade security fine-tuning ai models multilingual capabilities healthcare finance education legal information technology & services finance technology financial services enterprise software enterprises computer software consumer internet consumers internet research & development e-learning education management data analytics health care health wellness & fitness hospital & health care
Location
Las Vegas, Nevada, United States
Signals
CC
Claudia Canas
Self-Directed Investor | Former Biotech Quality Director at Vertex Pharmaceuticals
Vertex Pharmaceuticals
Focus areas
research cystic fibrosis alpha1 antitrypsin deficiency apol1mediated kidney diseases sickle cell disease beta thalassemia duchenne muscular dystrophy type 1 diabetes mellitus pharmaceuticals life sciences biotechnology: pharmaceutical preparations health care biotechnology research biopharmaceuticals innovative medicines gene editing crispr specialty markets transformative therapies rare genetic disorders precision medicine patient care scientific innovation drug development cftr modulators cell therapy pain management healthcare professionals global presence customer satisfaction patient demographics inclusion diversity equity acquisitions research facilities biotechnology chronic diseases fda approvals market leadership competitive landscape therapeutic areas patient advocacy healthcare solutions transformative healthcare crispr therapy genetic disorders clinical trials rare diseases apol1-mediated kidney disease type 1 diabetes transformative medicines research and development patient engagement innovative therapies fda approval drug discovery mrna technology employee giving corporate responsibility environmental sustainability clinical data medical advancements vertex foundation inclusion and diversity healthcare innovations scientific research partner collaborations patient access programs early access medicines transformative treatments regulatory compliance patient support healthcare equity community engagement scientific education stem initiatives pharmaceutical development safety and quality assurance adverse event reporting global outreach disease awareness patients-first approach manufacturing operations biotech collaboration clinical programs real-world evidence b2b services medical health wellness & fitness hospital & health care research & development
Location
Boston, Massachusetts, United States
Signals
DM
Diana McKenzie
Board Member
Vertex Pharmaceuticals
Focus areas
research cystic fibrosis alpha1 antitrypsin deficiency apol1mediated kidney diseases sickle cell disease beta thalassemia duchenne muscular dystrophy type 1 diabetes mellitus pharmaceuticals life sciences biotechnology: pharmaceutical preparations health care biotechnology research biopharmaceuticals innovative medicines gene editing crispr specialty markets transformative therapies rare genetic disorders precision medicine patient care scientific innovation drug development cftr modulators cell therapy pain management healthcare professionals global presence customer satisfaction patient demographics inclusion diversity equity acquisitions research facilities biotechnology chronic diseases fda approvals market leadership competitive landscape therapeutic areas patient advocacy healthcare solutions transformative healthcare crispr therapy genetic disorders clinical trials rare diseases apol1-mediated kidney disease type 1 diabetes transformative medicines research and development patient engagement innovative therapies fda approval drug discovery mrna technology employee giving corporate responsibility environmental sustainability clinical data medical advancements vertex foundation inclusion and diversity healthcare innovations scientific research partner collaborations patient access programs early access medicines transformative treatments regulatory compliance patient support healthcare equity community engagement scientific education stem initiatives pharmaceutical development safety and quality assurance adverse event reporting global outreach disease awareness patients-first approach manufacturing operations biotech collaboration clinical programs real-world evidence b2b services medical health wellness & fitness hospital & health care research & development
Location
Wilmington, North Carolina, United States
Signals
Edward Chung profile photo Bio-Rad Laboratories logo
Edward Chung
Vice President, Investor Relations
Bio-Rad Laboratories
Focus areas
research laboratory instruments apparatus consumables for life science research products used to separate purify identify analyze amplify biological materials laboratory diagnostics products to support monitoring & treatment of diseases biotechnology life sciences capital goods biotechnology research life science research clinical diagnostics in-vitro diagnostics antibodies chromatography digital droplet technology flow cytometry electrophoresis molecular testing autoimmune testing diabetes testing infectious disease testing blood typing quality control scientific discovery healthcare solutions pharmaceutical research environmental monitoring food safety gene expression protein purification drug discovery academic institutions hospitals public health laboratories biopharma customer-centric innovation global reach advanced technologies scientific education digital biology precision quantification customer satisfaction diverse customer base market trends competitive landscape life science bioprocessing translational research immunoassays pcr qpcr serology testing sample preparation cell isolation digital pcr molecular diagnostics newborn screening toxicity testing food safety testing biotechnology education protein characterization gene expression analysis mutagenesis detection bioproduction wastewater surveillance data management systems proficiency testing quality management custom pcr solutions remote diagnostics laboratory accreditation scientific research fluorescent imaging viral vector characterization medical testing serum indices analytical performance monitoring clinical chemistry pathogen detection protein quantification therapeutic drug monitoring educational training research products laboratory workflow optimization analytical methods validation b2b e-commerce services hospital & health care consumer internet consumers internet information technology & services
Location
Orinda, California, United States
Signals
GS
Gary Sapp
Institutional Review Board (IRB) Administrator
Battelle
Focus areas
research consumer industrial energy environment health analytics lab management national security stem education pharmaceutical medical devices infrastructure homeland security research services defense technology advanced manufacturing research commercialization advanced engineering laboratory operations nuclear submarine research remote sensing in ecology biodefense solutions research and development in the physical engineering and life sciences biological research services b2b nuclear reactor development x-ray and imaging technology ecological forecasting laboratory management environmental monitoring operational efficiency carbon capture and storage biological threat detection chemical research scientific innovation climate change adaptation bioremediation data science environmental impact assessment regulatory compliance uranium fabrication nuclear research public health energy security technologies energy efficiency advanced sensor technology nuclear security national laboratories research applied science chemical countermeasures education scientific research ecological assessment energy solutions data analytics environmental services consulting healthcare ecological monitoring technology commercialization climate resilience strategies polar research logistics ecological observatories defense philanthropy nuclear energy research and development innovation management science policy innovation government environmental remediation biotechnology pfas chemical replacement materials science medical device innovation cybersecurity public-private partnerships technology development community engagement advanced metallurgy military technology federally funded research defense and security advanced materials biotech solutions climate resilience advanced technology health solutions biological defense energy research emerging contaminants environmental sustainability aerospace materials government contracts commercial partnerships carbon capture biotechnology research engineering solutions research projects bioforensics pfas remediation infrastructure support transportation technologies ravenstar antenna polar research sustainable energy equipment testing contaminant investigation clean hydrogen hub educational programs nuclear energy research technical consulting research management material science defense solutions chemical analysis systematic innovation emerging threats applied research scientific discovery environmental regulations non-profit manufacturing distribution transportation information technology & services medical hospital & health care wellness & fitness renewables & environment health care research & development nonprofit organization management mechanical or industrial engineering
Location
Hilliard, Ohio, United States
Signals
Liza Heapes profile photo BeOne Medicines logo
Liza Heapes
Senior Director, Investor Relations
BeOne Medicines
Focus areas
research oncology hematology cancer treatment solid tumor targeted therapy biotechnology: pharmaceutical preparations health care biotechnology research immunotherapy cancer therapy personalized cancer medicine regulatory approvals regulatory approval patient enrollment cancer treatment equity pharmaceuticals cancer biomarker cancer drug pipeline checkpoint inhibitors b2b global health impact cdacs biotech pipeline drug development oncology drugs protein degradation regulatory strategy clinical trials global oncology clinical research collaboration next-generation cancer treatments cancer treatment affordability biotech research artificial intelligence drug acceleration bruton's tyrosine kinase inhibitors biopharma innovation cancer treatments antibody drug conjugates biotech manufacturing biotech regulatory strategy pipeline healthcare pharmaceutical and medicine manufacturing immuno-oncology blood cancers solid tumors biotechnology biotech next-generation oncology cancer drug innovation biotech company cancer combination therapy cancer immunotherapy oncology innovation cancer treatment development biotech global expansion oncology clinical trial design biotech innovation services cancer patient advocacy cancer care oncology biomarkers biotech r&d patient access biopharma cancer treatment access clinical research clinical development therapeutic development oncology pipeline cancer research global presence global biotech biopharmaceutical cancer pipeline neoadjuvant therapy global clinical trials innovative medicines adjuvant therapy biosimilar development targeted cancer therapy manufacturing hospital & health care health wellness & fitness medical information technology & services mechanical or industrial engineering
Location
Massachusetts, United States
Signals
NT
Nancy Thornberry
Member, Board of Directors
Vertex Pharmaceuticals
Focus areas
research cystic fibrosis alpha1 antitrypsin deficiency apol1mediated kidney diseases sickle cell disease beta thalassemia duchenne muscular dystrophy type 1 diabetes mellitus pharmaceuticals life sciences biotechnology: pharmaceutical preparations health care biotechnology research biopharmaceuticals innovative medicines gene editing crispr specialty markets transformative therapies rare genetic disorders precision medicine patient care scientific innovation drug development cftr modulators cell therapy pain management healthcare professionals global presence customer satisfaction patient demographics inclusion diversity equity acquisitions research facilities biotechnology chronic diseases fda approvals market leadership competitive landscape therapeutic areas patient advocacy healthcare solutions transformative healthcare crispr therapy genetic disorders clinical trials rare diseases apol1-mediated kidney disease type 1 diabetes transformative medicines research and development patient engagement innovative therapies fda approval drug discovery mrna technology employee giving corporate responsibility environmental sustainability clinical data medical advancements vertex foundation inclusion and diversity healthcare innovations scientific research partner collaborations patient access programs early access medicines transformative treatments regulatory compliance patient support healthcare equity community engagement scientific education stem initiatives pharmaceutical development safety and quality assurance adverse event reporting global outreach disease awareness patients-first approach manufacturing operations biotech collaboration clinical programs real-world evidence b2b services medical health wellness & fitness hospital & health care research & development
Location
New York, New York, United States
Signals
Neil Patel profile photo Gilead Sciences logo
Neil Patel
Director, Investor Relations
Gilead Sciences
Focus areas
research enterprise software big data cloud computing recruiting software information technology biotechnology: biological products (no diagnostic substances) health care biotechnology research biopharmaceuticals innovative medicines hiv aids hepatitis oncology inflammation antiviral therapies health equity patient care transformative therapies virology chronic diseases healthcare providers global access research and development clinical trials pre-exposure prophylaxis single-pill regimens cancer therapies serious respiratory conditions cardiovascular diseases patient demographics healthcare partnerships community impact drug discovery market access pharmaceutical innovation therapeutic areas health equity initiatives patient education global health chronic inflammatory conditions healthcare solutions life-threatening diseases viral hepatitis covid-19 emerging viruses antiviral treatments pharmaceutical development research funding patient safety medications therapeutic pipeline community engagement chronic inflammation treatments public health long-acting treatment hepatitis cure diversity in clinical trials global health access sustainability corporate giving employee resource groups consumer health data privacy anti-counterfeiting authorized distributors u.s. patient access research collaborations innovation in healthcare global workforce clinical research programs science and technology employee inclusion research publications adverse event reporting corporate responsibility strategic initiatives community outreach health education programs global operations pipeline management clinical development social impact health disparities b2b services enterprises computer software information technology & services health wellness & fitness hospital & health care research & development environmental services renewables & environment
Location
San Francisco, California, United States
Signals
SW
Sandra Wagner
Board Member
Novonesis
Focus areas
research biotechnology research biosolutions microbiology sustainable innovation food and beverage human health planetary health prebiotics probiotics enzymes nutritional profiles environmental sustainability animal health bioenergy circular plastics carbon capture agricultural biosolutions dietary supplements industrial bioprocessing sustainable production health management customer collaboration scientific excellence sustainable nutrition innovative solutions cleaner production waste reduction resource optimization plant-based solutions global impact health-conscious consumers diverse industries co-creation market leader transformative solutions sustainability microorganisms functional proteins healthier foods biofuel production animal nutrition plant health household cleaning products shelf life extension cleaner production processes higher crop yields climate action industrial biotech nutritional supplements health benefits sustainable agriculture conducting r&d food safety environmental impact emission reduction sustainable investing corporate governance green technologies diversity and inclusion job creation financial performance stock information analyst coverage investment opportunities clean energy solutions circular economy human welfare social responsibility climate neutrality healthier planet microbial solutions plant-based foods industrial applications advanced protein solutions b2b consulting services food & beverages consumer goods consumers health wellness & fitness environmental services renewables & environment
Location
Chicago, Illinois, United States
Signals
Sarah Chan profile photo Sage Bionetworks logo
Sarah Chan
Principal, Strategic Partnerships
Sage Bionetworks
Focus areas
research distributive research communities mobile health design & development of smartphone enabled clinical research studies computational & systems biolgoy technology platforms & services dream challenges data science
Location
Seattle, Washington, United States
Signals
SV
Seulkee Vyborney
Board Liaison, Executive Business Partner
OpenAI
Focus areas
research artificial intelligence & machine learning research services ai in startups ai collaboration ai in healthcare ai for business ai model api ai deployment ai model fine-tuning market research ai for data analysis ai model safety services ai for startups software development ai for automation ai for real-world interaction ai for personalized education ai models api ai for enterprises financial technology ai in finance content generation ai for research ai for medical research ai collaboration tools ai bias mitigation research and development in the physical engineering and life sciences ai scalability video generation models ai tools multimodal ai healthcare technology ai technology ai research community ai for healthcare ai infrastructure information technology and services ai models synthetic voices machine learning government ai responsible ai ai api platform ai applications ai for content creators ai for customer support ai model optimization ai solutions ai safety ai in industry ai model training gpt-4 reinforcement learning ai for education ai for content generation ai research ai innovation ai automation tools ai development ai safety protocols ai safety measures ai content creation ai for legal professionals ai model evaluation ai for decision making ai ethics ai ethics guidelines agi safety ai for social good ai model security b2b ai ai for finance chatgpt ai multimodal d2c cloud computing ai safety research ai creative applications ai for developers ai for scientific discovery ai in creative arts e-commerce ai model innovation b2c ai for language understanding ai model collaboration ai developer tools ai model customization gpt models ai for speech recognition natural language processing ai creative tools deep learning consulting ai for productivity artificial intelligence openai api ai for visual content ai model robustness ai productivity tools ai in education ai model deployment ai in enterprise ai multimodal inputs retail ai apis ai for enterprise solutions ai model interpretability ai model integration multimodal models ai model multimodal ai for environmental monitoring research and development education technology ai responsible development content creation ai model scalability openai sora text-to-video data analysis image generation api integration enterprise ai customizable ai models business productivity collaborative tools workforce empowerment financial analysis education ai academic research advanced ai tools task automation coding assistance multimedia understanding business insights team collaboration safety in ai ethical ai deployment customer service ai training datasets document summarization social implications of ai creative brainstorming personalized learning ai voice interaction image understanding secure ai solutions siri integration real-time reasoning custom gpts memory management in ai ai productivity user-friendly ai ai-driven insights enterprise-grade security fine-tuning ai models multilingual capabilities healthcare finance education legal information technology & services finance technology financial services enterprise software enterprises computer software consumer internet consumers internet research & development e-learning education management data analytics health care health wellness & fitness hospital & health care
Location
Oakland, California, United States
Signals
Tim Andrews profile photo Kilobaser logo
Tim Andrews
Angel Investor
Kilobaser
Focus areas
research biotechnology microfluidic automation life sciences dna synthesis microfluidics science hardware electronics dna oligos dna primer dna probe life science pressurevalve system rna synthesis labroutine synthesis microfluidic chip qpcr rtpcr taqman fishprobe rna rnasynthesis dnasynthesizer rnasynthesizer dnamodification
Location
Concord, Massachusetts, United States
Signals

Explore other regions in United States